对于心脏病综合征的新兴设备疗法
1University of Chicago Medicine, Heart and Vascular Center, Chicago, Illinois.
概括
了解心综合征 (CRS) 的最新进展强调静脉拥堵是关键因素. 针对透和塞的新型设备正在开发中,以改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 医疗器械 医疗器械
背景情况:
- 心脏病综合征 (CRS) 涉及心脏和脏之间的复杂相互作用,最近在分类和了解病理生物学方面取得了进展.
- 用CRS治疗急性心力衰竭的传统治疗依赖于利尿剂和液体限制,但最近的数据显示存在局限性.
- 仅仅关注心脏输出量低的CRS的既定观点正在受到新的证据的挑战,这些证据涉及脏静脉拥堵.
研究的目的:
- 审查对心脏脏综合征 (CRS) 病理生理学和血液动力学障碍的不断变化的理解.
- 探索针对急性 (I型) CRS 的新型循环辅助器件.
- 评估这些新设备在改善功能和管理塞方面的潜力.
主要方法:
- 审查最近的临床前和临床观察,挑战传统的CRS血液动力学模型.
- 新型辅助器件的分类为"推进器" (改善 perfusion) 和"拉动器" (减少静脉拥堵).
- 对有前途的器械疗法的早期临床研究数据的分析.
主要成果:
- 脏静脉堵塞/高血压被认为是CRS的重要贡献者,影响脏 perfusion 压力.
- 新型设备,分为"推进器"和"拉出器",在早期研究中显示出治疗急性CRS的前景.
- 到目前为止,美国还没有获得CRS的循环辅助器件的商业批准.
结论:
- 对心脏脏综合征 (CRS) 病理生理学的理解已经超越了低心脏输出,包括脏静脉拥堵.
- 新兴设备疗法为治疗急性CRS提供了新的途径,通过解决动脉低 perfusion 和静脉拥堵.
- 这些CRS器件疗法的最终临床价值将取决于它们的安全性和在功能和塞标志物中实现有意义的,持久的改善的能力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:25Antihypertensive Drugs: Direct Renin Inhibitors
517
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
517
01:27Dialysis
281
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
281
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
569
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
569